Literature DB >> 16000577

Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients.

Jenny Chang-Claude1, Odilia Popanda, Xiang-Lin Tan, Silke Kropp, Irmgard Helmbold, Dietrich von Fournier, Wulf Haase, Marie Luise Sautter-Bihl, Frederik Wenz, Peter Schmezer, Christine B Ambrosone.   

Abstract

PURPOSE: Several DNA repair gene polymorphisms have been described, which affect DNA repair capacity and modulate cancer susceptibility. We evaluated the association of six polymorphisms in the DNA repair genes: XRCC1 (Arg194Trp, Arg280His, and Arg399Gln), APE1 (Asp148Glu), and XPD (Lys751Gln and Asp312Asn), with the risk of acute skin reactions following radiotherapy.
DESIGN: We conducted a prospective study of 446 female patients with breast cancer who received radiotherapy after breast-conserving surgery. Individual genetic polymorphisms were determined using melting point analysis of sequence-specific hybridization probes. The development of acute skin reactions (moist desquamation) associated with DNA repair gene polymorphisms was modeled using Cox proportional hazards, accounting for cumulative biologically effective radiation dose.
RESULTS: Overall, the development of acute toxicity, which presented in 77 patients, was not associated with the genetic variants studied, although the hazard ratios (HR) were generally below 1. Risks were however differential by body mass index. Among normal-weight patients only, both carriers of the APE1 148Glu and the XRCC1 399Gln alleles had decreased risk of acute skin reactions after radiotherapy (HR, 0.49 and 0.51, respectively). The results for XRCC1 were confirmed by haplotype analysis. When considering joint effects, we observed that compared with homozygote carriers of the wild-type allele in both genes, the risk was most strongly reduced in carriers of both APE1 148Glu and XRCC1 399Gln alleles with normal weight [HR, 0.19; 95% confidence interval (95% CI), 0.06-0.56] but not in those with overweight (HR, 1.39; 95% CI, 0.56-3.45; Pinteraction = 0.009).
CONCLUSION: The XRCC1 399Gln or APE1 148Glu alleles may be protective against the development of acute side effects after radiotherapy in patients with normal weight.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000577     DOI: 10.1158/1078-0432.CCR-04-2657

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

1.  DNA repair gene variants in endometrial carcinoma.

Authors:  Zeynep Birsu Cincin; Ahmet Cem Iyibozkurt; Sibel Bulgurcuoglu Kuran; Bedia Cakmakoglu
Journal:  Med Oncol       Date:  2012-01-22       Impact factor: 3.064

2.  Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity.

Authors:  Sebastian Reuther; Silke Szymczak; Annette Raabe; Kerstin Borgmann; Andreas Ziegler; Cordula Petersen; Ekkehard Dikomey; Ulrike Hoeller
Journal:  Strahlenther Onkol       Date:  2014-08-26       Impact factor: 3.621

Review 3.  Second malignant neoplasms and cardiovascular disease following radiotherapy.

Authors:  Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice
Journal:  J Natl Cancer Inst       Date:  2012-02-06       Impact factor: 13.506

4.  XRCC1 R399Q polymorphism and risk of normal tissue injury after radiotherapy in breast cancer patients.

Authors:  Yingying Zhou; Weibing Zhou; Qiong Liu; Zhiru Fan; Zhen Yang; Qingsong Tu; Li Li; Haifeng Liu
Journal:  Tumour Biol       Date:  2013-12-03

5.  Susceptibility of peripheral lymphocytes of brain tumour patients to in vitro radiation-induced DNA damage, a preliminary study.

Authors:  Guruprasad Kalthur; Prem Kumar; Uma Devi; Sabir Ali; Ramya Upadhya; Sailaja Pillai; Anjali Rao
Journal:  Clin Exp Med       Date:  2008-09-13       Impact factor: 3.984

6.  Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.

Authors:  Tasha R Smith; Wen Liu-Mares; Beth O Van Emburgh; Edward A Levine; Glenn O Allen; Jeff W Hill; Isildinha M Reis; Laura A Kresty; Mark D Pegram; Mark S Miller; Jennifer J Hu
Journal:  Carcinogenesis       Date:  2011-06-23       Impact factor: 4.944

7.  Molecular biomarkers in the decision of treatment of cervical carcinoma patients.

Authors:  A Valenciano; L A Henríquez-Hernández; M Lloret; B Pinar; P C Lara
Journal:  Clin Transl Oncol       Date:  2013-02-22       Impact factor: 3.405

8.  Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.

Authors:  Marjun P Duldulao; Wendy Lee; Rebecca A Nelson; Joyce Ho; Maithao Le; Zhenbin Chen; Wenyan Li; Joseph Kim; Julio Garcia-Aguilar
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

Review 9.  Polymorphisms in base excision repair genes: Breast cancer risk and individual radiosensitivity.

Authors:  Clarice Patrono; Silvia Sterpone; Antonella Testa; Renata Cozzi
Journal:  World J Clin Oncol       Date:  2014-12-10

10.  Haplotype-tagging single nucleotide polymorphisms in the GSTP1 gene promoter and susceptibility to lung cancer.

Authors:  Xiang-Lin Tan; Roxana Moslehi; WeiGuo Han; Simon D Spivack
Journal:  Cancer Detect Prev       Date:  2009-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.